IPHYF
Price
$2.06
Change
+$0.75 (+57.25%)
Updated
Aug 11 closing price
Capitalization
204.48M
MEOBF
Price
$1.54
Change
+$0.03 (+1.99%)
Updated
Aug 14 closing price
Capitalization
2.03B
12 days until earnings call
Interact to see
Advertisement

IPHYF vs MEOBF

Header iconIPHYF vs MEOBF Comparison
Open Charts IPHYF vs MEOBFBanner chart's image
Innate Pharma
Price$2.06
Change+$0.75 (+57.25%)
Volume$300
Capitalization204.48M
Mesoblast
Price$1.54
Change+$0.03 (+1.99%)
Volume$1.95K
Capitalization2.03B
IPHYF vs MEOBF Comparison Chart in %
Loading...
IPHYF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MEOBF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IPHYF vs. MEOBF commentary
Aug 16, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IPHYF is a Buy and MEOBF is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 16, 2025
Stock price -- (IPHYF: $2.06 vs. MEOBF: $1.54)
Brand notoriety: IPHYF and MEOBF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IPHYF: 53% vs. MEOBF: 258%
Market capitalization -- IPHYF: $204.48M vs. MEOBF: $2.03B
IPHYF [@Biotechnology] is valued at $204.48M. MEOBF’s [@Biotechnology] market capitalization is $2.03B. The market cap for tickers in the [@Biotechnology] industry ranges from $100.07B to $0. The average market capitalization across the [@Biotechnology] industry is $1.85B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IPHYF’s FA Score shows that 0 FA rating(s) are green whileMEOBF’s FA Score has 0 green FA rating(s).

  • IPHYF’s FA Score: 0 green, 5 red.
  • MEOBF’s FA Score: 0 green, 5 red.
According to our system of comparison, MEOBF is a better buy in the long-term than IPHYF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IPHYF’s TA Score shows that 4 TA indicator(s) are bullish while MEOBF’s TA Score has 2 bullish TA indicator(s).

  • IPHYF’s TA Score: 4 bullish, 3 bearish.
  • MEOBF’s TA Score: 2 bullish, 2 bearish.
According to our system of comparison, both IPHYF and MEOBF are a good buy in the short-term.

Price Growth

IPHYF (@Biotechnology) experienced а +57.21% price change this week, while MEOBF (@Biotechnology) price change was +1.99% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.94%. For the same industry, the average monthly price growth was +21.39%, and the average quarterly price growth was +21.23%.

Reported Earning Dates

MEOBF is expected to report earnings on Aug 27, 2025.

Industries' Descriptions

@Biotechnology (+5.94% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MEOBF($2.03B) has a higher market cap than IPHYF($204M). IPHYF (-28.983) and MEOBF (-30.000) have similar YTD gains .
IPHYFMEOBFIPHYF / MEOBF
Capitalization204M2.03B10%
EBITDAN/A-77.78M-
Gain YTD-28.983-30.00097%
P/E RatioN/AN/A-
RevenueN/A5.67M-
Total CashN/A37.7M-
Total DebtN/A126M-
FUNDAMENTALS RATINGS
IPHYF vs MEOBF: Fundamental Ratings
IPHYF
MEOBF
OUTLOOK RATING
1..100
4143
VALUATION
overvalued / fair valued / undervalued
1..100
76
Overvalued
88
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9596
PRICE GROWTH RATING
1..100
3937
P/E GROWTH RATING
1..100
10057
SEASONALITY SCORE
1..100
n/a85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IPHYF's Valuation (76) in the null industry is in the same range as MEOBF (88). This means that IPHYF’s stock grew similarly to MEOBF’s over the last 12 months.

IPHYF's Profit vs Risk Rating (100) in the null industry is in the same range as MEOBF (100). This means that IPHYF’s stock grew similarly to MEOBF’s over the last 12 months.

IPHYF's SMR Rating (95) in the null industry is in the same range as MEOBF (96). This means that IPHYF’s stock grew similarly to MEOBF’s over the last 12 months.

MEOBF's Price Growth Rating (37) in the null industry is in the same range as IPHYF (39). This means that MEOBF’s stock grew similarly to IPHYF’s over the last 12 months.

MEOBF's P/E Growth Rating (57) in the null industry is somewhat better than the same rating for IPHYF (100). This means that MEOBF’s stock grew somewhat faster than IPHYF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IPHYFMEOBF
RSI
ODDS (%)
Bearish Trend 2 days ago
55%
Bearish Trend 2 days ago
50%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
58%
Bearish Trend 2 days ago
64%
Momentum
ODDS (%)
Bullish Trend 2 days ago
54%
N/A
MACD
ODDS (%)
Bullish Trend 2 days ago
53%
N/A
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
46%
Bullish Trend 2 days ago
52%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
41%
Bullish Trend 2 days ago
50%
Advances
ODDS (%)
N/A
N/A
Declines
ODDS (%)
N/A
N/A
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
55%
Bullish Trend 2 days ago
61%
View a ticker or compare two or three
Interact to see
Advertisement
IPHYF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MEOBF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
APDHX26.410.05
+0.19%
Artisan Global Equity Advisor
FMPOX30.38N/A
N/A
Fidelity Advisor Mid Cap Value I
JHISX13.34-0.01
-0.07%
Janus Henderson VIT Global Sust Eq Ins
MRERX52.91-0.07
-0.13%
MFS Core Equity R2
TVLYX12.47-0.05
-0.40%
Touchstone Value Y

IPHYF and

Correlation & Price change

A.I.dvisor indicates that over the last year, IPHYF has been loosely correlated with MBIO. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if IPHYF jumps, then MBIO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IPHYF
1D Price
Change %
IPHYF100%
N/A
MBIO - IPHYF
42%
Loosely correlated
-4.81%
HLVX - IPHYF
38%
Loosely correlated
+0.48%
SLRX - IPHYF
33%
Loosely correlated
-6.43%
RVMD - IPHYF
30%
Poorly correlated
-0.14%
GRI - IPHYF
28%
Poorly correlated
+10.77%
More

MEOBF and

Correlation & Price change

A.I.dvisor tells us that MEOBF and RLYB have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MEOBF and RLYB's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MEOBF
1D Price
Change %
MEOBF100%
+1.99%
RLYB - MEOBF
25%
Poorly correlated
+1.98%
ADIL - MEOBF
24%
Poorly correlated
-1.38%
MMIRF - MEOBF
10%
Poorly correlated
N/A
MLLCF - MEOBF
6%
Poorly correlated
N/A
IPHYF - MEOBF
5%
Poorly correlated
N/A
More